{"transactions":[{"id":4631089,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-05T22:05:55.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":false,"shares":17750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":151416,"derivative":{"exercise_price":4.46,"expiration_date":"2032-07-19","underlying":"Common Stock","underlying_shares":17750},"source":{"system":"sec-edgar","filing":"0001807359-26-000018","document":"wk-form4_1791237952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000018/wk-form4_1791237952.xml","form_type":"4"}},{"id":4631088,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-10-05T22:05:55.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":900,"price":36.57,"value":32913.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026."}],"balance_after":14954,"source":{"system":"sec-edgar","filing":"0001807359-26-000018","document":"wk-form4_1791237952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000018/wk-form4_1791237952.xml","form_type":"4"}},{"id":4631087,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-10-05T22:05:55.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":16850,"price":36.08,"value":607948.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $36.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026."}],"balance_after":15854,"source":{"system":"sec-edgar","filing":"0001807359-26-000018","document":"wk-form4_1791237952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000018/wk-form4_1791237952.xml","form_type":"4"}},{"id":4631086,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-10-05T22:05:55.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":true,"shares":17750,"price":4.46,"value":79165.0,"ownership":{"direct":true},"balance_after":32704,"source":{"system":"sec-edgar","filing":"0001807359-26-000018","document":"wk-form4_1791237952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000018/wk-form4_1791237952.xml","form_type":"4"}},{"id":4624135,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-18T22:56:09.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":10531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."}],"balance_after":10531,"derivative":{"exercise_price":39.57,"expiration_date":"2036-09-15","underlying":"Common Shares","underlying_shares":10531},"source":{"system":"sec-edgar","filing":"0001807359-26-000016","document":"wk-form4_1789772167.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000016/wk-form4_1789772167.xml","form_type":"4"}},{"id":4624134,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-18T22:56:09.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":5054,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."}],"balance_after":14954,"source":{"system":"sec-edgar","filing":"0001807359-26-000016","document":"wk-form4_1789772167.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000016/wk-form4_1789772167.xml","form_type":"4"}},{"id":4622116,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-17T22:43:13.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":600,"price":40.38,"value":24228.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.25 to $40.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026."}],"balance_after":9900,"source":{"system":"sec-edgar","filing":"0001807359-26-000014","document":"wk-form4_1789684991.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000014/wk-form4_1789684991.xml","form_type":"4"}},{"id":4622115,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-17T22:43:13.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":4338,"price":39.65,"value":172001.7,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.25 to $40.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026."}],"balance_after":10500,"source":{"system":"sec-edgar","filing":"0001807359-26-000014","document":"wk-form4_1789684991.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000014/wk-form4_1789684991.xml","form_type":"4"}},{"id":4617449,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-14T22:34:01.000Z","date":"2026-09-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":2179,"price":40.94,"value":89208.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":14838,"source":{"system":"sec-edgar","filing":"0001807359-26-000012","document":"wk-form4_1789425238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000012/wk-form4_1789425238.xml","form_type":"4"}},{"id":705208,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2026-07-22T01:00:17.000Z","date":"2026-07-17","kind":"grant","planned":false,"acquired":true,"shares":543,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":17017,"source":{"system":"sec-edgar","filing":"0001140361-26-029192","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036126029192/form4.xml","form_type":"4"}},{"id":721336,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T22:34:22.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":17750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":169166,"derivative":{"exercise_price":4.46,"expiration_date":"2032-07-19","underlying":"Common Stock","underlying_shares":17750},"source":{"system":"sec-edgar","filing":"0001807359-26-000010","document":"wk-form4_1782945259.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000010/wk-form4_1782945259.xml","form_type":"4"}},{"id":721335,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T22:34:22.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":2748,"price":34.71,"value":95383.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.65 to $34.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":16474,"source":{"system":"sec-edgar","filing":"0001807359-26-000010","document":"wk-form4_1782945259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000010/wk-form4_1782945259.xml","form_type":"4"}},{"id":721334,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T22:34:22.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":15002,"price":34.32,"value":514868.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":19222,"source":{"system":"sec-edgar","filing":"0001807359-26-000010","document":"wk-form4_1782945259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000010/wk-form4_1782945259.xml","form_type":"4"}},{"id":721333,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T22:34:22.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":17750,"price":4.46,"value":79165.0,"ownership":{"direct":true},"balance_after":34224,"source":{"system":"sec-edgar","filing":"0001807359-26-000010","document":"wk-form4_1782945259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000010/wk-form4_1782945259.xml","form_type":"4"}},{"id":730559,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:13:47.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.28,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001807359-26-000008","document":"wk-form4_1782159224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180735926000008/wk-form4_1782159224.xml","form_type":"4"}},{"id":803753,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-04-21T22:34:05.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":16474,"source":{"system":"sec-edgar","filing":"0001807359-26-000006","document":"wk-form4_1776810842.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000006/wk-form4_1776810842.xml","form_type":"4"}},{"id":835096,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-03-18T22:23:29.000Z","date":"2026-03-16","kind":"sale","planned":false,"acquired":false,"shares":41861,"price":28.68,"value":1200573.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $28.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":15804,"source":{"system":"sec-edgar","filing":"0001807359-26-000004","document":"wk-form4_1773872606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000004/wk-form4_1773872606.xml","form_type":"4"}},{"id":933454,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2026-01-23T02:00:29.000Z","date":"2026-01-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":54,"price":22.98,"value":1240.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":57665,"source":{"system":"sec-edgar","filing":"0001140361-26-002085","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036126002085/form4.xml","form_type":"4"}},{"id":933453,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2026-01-23T02:00:29.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":815,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":57719,"source":{"system":"sec-edgar","filing":"0001140361-26-002085","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036126002085/form4.xml","form_type":"4"}},{"id":1014753,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-10-23T01:01:02.000Z","date":"2025-10-20","kind":"grant","planned":false,"acquired":true,"shares":1056,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":56904,"source":{"system":"sec-edgar","filing":"0001140361-25-038997","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036125038997/form4.xml","form_type":"4"}},{"id":1041657,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-13T01:00:19.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":33726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date."}],"balance_after":33726,"derivative":{"exercise_price":13.77,"expiration_date":"2035-09-09","underlying":"Common Shares","underlying_shares":33726},"source":{"system":"sec-edgar","filing":"0001140361-25-034929","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036125034929/form4.xml","form_type":"4"}},{"id":1041656,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-09-13T01:00:19.000Z","date":"2025-09-10","kind":"other","planned":false,"acquired":false,"shares":1661,"price":13.77,"value":22871.97,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":55848,"source":{"system":"sec-edgar","filing":"0001140361-25-034929","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036125034929/form4.xml","form_type":"4"}},{"id":1041655,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-09-13T01:00:19.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":14524,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date."}],"balance_after":57509,"source":{"system":"sec-edgar","filing":"0001140361-25-034929","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036125034929/form4.xml","form_type":"4"}},{"id":1084065,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-07-22T01:00:19.000Z","date":"2025-07-17","kind":"grant","planned":false,"acquired":true,"shares":1609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":42985,"source":{"system":"sec-edgar","filing":"0001140361-25-026647","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036125026647/form4.xml","form_type":"4"}},{"id":1101745,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T20:37:40.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":0.6951,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-25-000064","document":"wk-form4_1750883852.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000064/wk-form4_1750883852.xml","form_type":"4"}},{"id":1168398,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-04-22T01:00:24.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":1847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":41376,"source":{"system":"sec-edgar","filing":"0001140361-25-014802","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036125014802/form4.xml","form_type":"4"}},{"id":1294556,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-01-28T02:00:29.000Z","date":"2025-01-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":180,"price":11.21,"value":2017.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":39529,"source":{"system":"sec-edgar","filing":"0001140361-25-002102","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036125002102/form4.xml","form_type":"4"}},{"id":1294555,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-01-28T02:00:29.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":1672,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":39709,"source":{"system":"sec-edgar","filing":"0001140361-25-002102","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036125002102/form4.xml","form_type":"4"}},{"id":1382398,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-10-24T01:00:20.000Z","date":"2024-10-21","kind":"grant","planned":false,"acquired":true,"shares":1613,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":38037,"source":{"system":"sec-edgar","filing":"0001140361-24-044060","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036124044060/form4.xml","form_type":"4"}},{"id":1406697,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-09-17T01:00:49.000Z","date":"2024-09-12","kind":"other","planned":false,"acquired":false,"shares":4245,"price":12.12,"value":51449.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":36424,"source":{"system":"sec-edgar","filing":"0001140361-24-041233","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036124041233/form4.xml","form_type":"4"}},{"id":1408723,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-13T01:00:21.000Z","date":"2024-09-10","kind":"grant","planned":false,"acquired":true,"shares":27894,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date."}],"balance_after":27894,"derivative":{"exercise_price":12.19,"expiration_date":"2034-09-09","underlying":"Common Shares","underlying_shares":27894},"source":{"system":"sec-edgar","filing":"0001140361-24-040987","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036124040987/form4.xml","form_type":"4"}},{"id":1408722,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-09-13T01:00:21.000Z","date":"2024-09-10","kind":"grant","planned":false,"acquired":true,"shares":16406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date."}],"balance_after":40669,"source":{"system":"sec-edgar","filing":"0001140361-24-040987","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036124040987/form4.xml","form_type":"4"}},{"id":1448721,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-07-26T01:00:53.000Z","date":"2024-07-23","kind":"grant","planned":false,"acquired":true,"shares":1702,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":24263,"source":{"system":"sec-edgar","filing":"0001140361-24-034279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036124034279/form4.xml","form_type":"4"}},{"id":1477410,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T21:37:24.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.56,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-24-000050","document":"wk-form4_1718660238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000050/wk-form4_1718660238.xml","form_type":"4"}},{"id":1534829,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-04-27T01:01:01.000Z","date":"2024-04-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":123,"price":10.9,"value":1340.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":22561,"source":{"system":"sec-edgar","filing":"0001140361-24-022617","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036124022617/form4.xml","form_type":"4"}},{"id":1534828,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-04-27T01:01:01.000Z","date":"2024-04-24","kind":"grant","planned":true,"acquired":true,"shares":1146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":22684,"source":{"system":"sec-edgar","filing":"0001140361-24-022617","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036124022617/form4.xml","form_type":"4"}},{"id":1546824,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T20:55:22.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":24.46,"expiration_date":"2031-06-11","underlying":"Common Stock","underlying_shares":20250},"source":{"system":"sec-edgar","filing":"0001415889-24-010429","document":"form4-04052024_040416.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000141588924010429/form4-04052024_040416.xml","form_type":"4"}},{"id":1546823,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T20:55:22.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":3.48,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-24-010429","document":"form4-04052024_040416.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000141588924010429/form4-04052024_040416.xml","form_type":"4"}},{"id":1546822,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T20:55:22.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":8.38,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":20250},"source":{"system":"sec-edgar","filing":"0001415889-24-010429","document":"form4-04052024_040416.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000141588924010429/form4-04052024_040416.xml","form_type":"4"}},{"id":1546821,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T20:55:22.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60751,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":8.39,"expiration_date":"2030-10-23","underlying":"Common Stock","underlying_shares":60751},"source":{"system":"sec-edgar","filing":"0001415889-24-010429","document":"form4-04052024_040416.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000141588924010429/form4-04052024_040416.xml","form_type":"4"}},{"id":1649467,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-13T01:22:44.000Z","date":"2024-02-12","kind":"sale","planned":false,"acquired":false,"shares":2573,"price":11.44,"value":29435.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.29 to $11.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":451449,"source":{"system":"sec-edgar","filing":"0001725160-24-000043","document":"wk-form4_1707787354.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516024000043/wk-form4_1707787354.xml","form_type":"4"}},{"id":1659088,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-06T00:12:40.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":75000,"derivative":{"exercise_price":11.69,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001725160-24-000028","document":"wk-form4_1707178346.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516024000028/wk-form4_1707178346.xml","form_type":"4"}},{"id":1659087,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-06T00:12:40.000Z","date":"2024-02-02","kind":"sale","planned":false,"acquired":false,"shares":8669,"price":11.54,"value":100040.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":454022,"source":{"system":"sec-edgar","filing":"0001725160-24-000028","document":"wk-form4_1707178346.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516024000028/wk-form4_1707178346.xml","form_type":"4"}},{"id":1659086,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-06T00:12:40.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":462691,"source":{"system":"sec-edgar","filing":"0001725160-24-000028","document":"wk-form4_1707178346.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516024000028/wk-form4_1707178346.xml","form_type":"4"}},{"id":1673146,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-01-24T02:00:30.000Z","date":"2024-01-19","kind":"grant","planned":false,"acquired":true,"shares":1207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":21538,"source":{"system":"sec-edgar","filing":"0001140361-24-003552","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036124003552/form4.xml","form_type":"4"}},{"id":1758185,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-10-19T01:30:21.000Z","date":"2023-10-16","kind":"grant","planned":false,"acquired":true,"shares":1226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":20331,"source":{"system":"sec-edgar","filing":"0001140361-23-048775","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036123048775/form4.xml","form_type":"4"}},{"id":1763702,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-10-06T23:18:52.000Z","date":"2023-10-04","kind":"sale","planned":true,"acquired":false,"shares":888,"price":19.9102,"value":17680.2576,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.91 to $19.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,125 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on March 31, 2023."}],"balance_after":387691,"source":{"system":"sec-edgar","filing":"0001725160-23-000179","document":"wk-form4_1696634321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516023000179/wk-form4_1696634321.xml","form_type":"4"}},{"id":1763701,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-10-06T23:18:52.000Z","date":"2023-10-04","kind":"sale","planned":true,"acquired":false,"shares":4594,"price":19.4265,"value":89245.341,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.91 to $19.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,125 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on March 31, 2023."}],"balance_after":388579,"source":{"system":"sec-edgar","filing":"0001725160-23-000179","document":"wk-form4_1696634321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516023000179/wk-form4_1696634321.xml","form_type":"4"}},{"id":1781105,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-15T01:31:15.000Z","date":"2023-09-12","kind":"grant","planned":false,"acquired":true,"shares":26595,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date."}],"balance_after":26595,"derivative":{"exercise_price":11.22,"expiration_date":"2033-09-11","underlying":"Common Shares","underlying_shares":26595},"source":{"system":"sec-edgar","filing":"0001140361-23-044045","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036123044045/form4.xml","form_type":"4"}},{"id":1781104,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-09-15T01:31:15.000Z","date":"2023-09-12","kind":"grant","planned":false,"acquired":true,"shares":17825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date."}],"balance_after":19105,"source":{"system":"sec-edgar","filing":"0001140361-23-044045","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036123044045/form4.xml","form_type":"4"}},{"id":1834022,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-07-07T01:30:23.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":1280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":1280,"source":{"system":"sec-edgar","filing":"0001140361-23-033547","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036123033547/form4.xml","form_type":"4"}},{"id":1852484,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T23:52:04.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":3.97,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-23-000059","document":"wf-form4_168695951498248.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000059/wf-form4_168695951498248.xml","form_type":"4"}},{"id":1857326,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-13T22:26:25.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 12, 2023 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date."}],"balance_after":25000,"derivative":{"exercise_price":3.48,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-036859","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000120919123036859/doc4.xml","form_type":"4"}},{"id":2016710,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-15T00:10:55.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":5227,"price":19.9753,"value":104410.8931,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires August 15, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.77 to $20.30. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":392048,"source":{"system":"sec-edgar","filing":"0001725160-23-000035","document":"wf-form4_167641983783824.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516023000035/wf-form4_167641983783824.xml","form_type":"4"}},{"id":2016709,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-15T00:10:55.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":2624,"price":20.4244,"value":53593.6256,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.79 to $20.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":397275,"source":{"system":"sec-edgar","filing":"0001725160-23-000035","document":"wf-form4_167641983783824.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516023000035/wf-form4_167641983783824.xml","form_type":"4"}},{"id":2038614,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-02T00:07:27.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":148043,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date."}],"balance_after":148043,"derivative":{"exercise_price":23.65,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":148043},"source":{"system":"sec-edgar","filing":"0001725160-23-000017","document":"wf-form4_167529642722449.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516023000017/wf-form4_167529642722449.xml","form_type":"4"}},{"id":2038613,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-02T00:07:27.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":101957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 399 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on March 31, 2022."}],"balance_after":399899,"source":{"system":"sec-edgar","filing":"0001725160-23-000017","document":"wf-form4_167529642722449.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516023000017/wf-form4_167529642722449.xml","form_type":"4"}},{"id":2147538,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-10-03T22:42:44.000Z","date":"2022-10-03","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted by the Issuer under the 2020 Incentive Award Plan, as amended.  The RSUs will vest over two years: 1/3 of the RSUs will vest on the first anniversary of the date of grant, and the remaining 2/3 of the RSUs will vest on the second anniversary of the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 129 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on September 30, 2022."}],"balance_after":297543,"source":{"system":"sec-edgar","filing":"0001725160-22-000180","document":"wf-form4_166483690075305.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516022000180/wf-form4_166483690075305.xml","form_type":"4"}},{"id":2202855,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-25T10:06:01.000Z","date":"2022-07-20","kind":"grant","acquired":true,"shares":186916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Award of stock options to purchase Common Shares with a vesting commencement date of June 29, 2022. These options vest and become exercisable (i) 1/3 on the first anniversary of the vesting commencement date and (ii) in twenty-four (24) successive equal monthly installments measured from the first anniversary of the vesting commencement date., subject to the reporting person's continuous service through the applicable vesting date."}],"balance_after":186916,"derivative":{"exercise_price":4.46,"expiration_date":"2032-07-19","underlying":"Common Shares","underlying_shares":186916},"source":{"system":"sec-edgar","filing":"0000899243-22-026615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000089924322026615/doc4.xml","form_type":"4"}},{"id":2230109,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T00:03:42.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":86467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":86467,"derivative":{"exercise_price":2.7,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":86467},"source":{"system":"sec-edgar","filing":"0001808805-22-000070","document":"wf-form4_165542420534044.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000070/wf-form4_165542420534044.xml","form_type":"4"}},{"id":2231555,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-15T21:00:23.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":20250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 13, 2022 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date."}],"balance_after":20250,"derivative":{"exercise_price":8.38,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":20250},"source":{"system":"sec-edgar","filing":"0001209191-22-037016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000120919122037016/doc4.xml","form_type":"4"}},{"id":2304891,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:53:12.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":353,"price":52.4386,"value":18510.8258,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.41 to $52.54. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":247414,"source":{"system":"sec-edgar","filing":"0001725160-22-000069","document":"wf-form4_164919917834645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516022000069/wf-form4_164919917834645.xml","form_type":"4"}},{"id":2304890,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:53:12.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":4512,"price":51.9862,"value":234561.7344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.41 to $52.40. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":247767,"source":{"system":"sec-edgar","filing":"0001725160-22-000069","document":"wf-form4_164919917834645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516022000069/wf-form4_164919917834645.xml","form_type":"4"}},{"id":2304889,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:53:12.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":2818,"price":50.6975,"value":142865.555,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.38 to $51.32. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":252279,"source":{"system":"sec-edgar","filing":"0001725160-22-000069","document":"wf-form4_164919917834645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516022000069/wf-form4_164919917834645.xml","form_type":"4"}},{"id":2304888,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:53:12.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":1303,"price":49.9018,"value":65022.0454,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.38 to $50.37. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":255097,"source":{"system":"sec-edgar","filing":"0001725160-22-000069","document":"wf-form4_164919917834645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516022000069/wf-form4_164919917834645.xml","form_type":"4"}},{"id":2304887,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:53:12.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":8094,"price":48.7475,"value":394562.265,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $48.35 to $49.33. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":256400,"source":{"system":"sec-edgar","filing":"0001725160-22-000069","document":"wf-form4_164919917834645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516022000069/wf-form4_164919917834645.xml","form_type":"4"}},{"id":2378876,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-24T01:12:06.000Z","date":"2022-02-23","kind":"sale","acquired":false,"shares":702,"price":49.589,"value":34811.478,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.49 to $49.75. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":264494,"source":{"system":"sec-edgar","filing":"0001725160-22-000047","document":"wf-form4_164566511121736.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516022000047/wf-form4_164566511121736.xml","form_type":"4"}},{"id":2378875,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-24T01:12:06.000Z","date":"2022-02-23","kind":"sale","acquired":false,"shares":1211,"price":48.8103,"value":59109.2733,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $48.49 to $49.36. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":265196,"source":{"system":"sec-edgar","filing":"0001725160-22-000047","document":"wf-form4_164566511121736.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516022000047/wf-form4_164566511121736.xml","form_type":"4"}},{"id":2398327,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T02:09:47.000Z","date":"2022-02-10","kind":"grant","acquired":true,"shares":38489,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date."}],"balance_after":38489,"derivative":{"exercise_price":52.61,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":38489},"source":{"system":"sec-edgar","filing":"0001725160-22-000033","document":"wf-form4_164489096835537.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516022000033/wf-form4_164489096835537.xml","form_type":"4"}},{"id":2398326,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-15T02:09:47.000Z","date":"2022-02-10","kind":"grant","acquired":true,"shares":16405,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date."}],"balance_after":266407,"source":{"system":"sec-edgar","filing":"0001725160-22-000033","document":"wf-form4_164489096835537.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516022000033/wf-form4_164489096835537.xml","form_type":"4"}},{"id":2552260,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-10-05T01:16:35.000Z","date":"2021-10-02","kind":"tax_withholding","acquired":false,"shares":17080,"price":67.13,"value":1146580.4,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 397 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on September 30, 2021."}],"balance_after":250002,"source":{"system":"sec-edgar","filing":"0001725160-21-000199","document":"wf-form4_163339657893202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000199/wf-form4_163339657893202.xml","form_type":"4"}},{"id":2595037,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-20T16:59:42.000Z","date":"2021-08-19","kind":"purchase","acquired":true,"shares":8285,"price":51.9976,"value":430800.116,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $51.93 to $52.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":266685,"source":{"system":"sec-edgar","filing":"0001725160-21-000185","document":"wf-form4_162947877030994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000185/wf-form4_162947877030994.xml","form_type":"4"}},{"id":2595036,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-20T16:59:42.000Z","date":"2021-08-18","kind":"purchase","acquired":true,"shares":1326,"price":51.997,"value":68948.022,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $51.96 to $52.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":258400,"source":{"system":"sec-edgar","filing":"0001725160-21-000185","document":"wf-form4_162947877030994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000185/wf-form4_162947877030994.xml","form_type":"4"}},{"id":2641493,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-07-07T00:01:08.000Z","date":"2021-07-01","kind":"sale","acquired":false,"shares":200,"price":53.185,"value":10637.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.15 to $53.22. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":257074,"source":{"system":"sec-edgar","filing":"0001725160-21-000163","document":"wf-form4_162561605028744.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000163/wf-form4_162561605028744.xml","form_type":"4"}},{"id":2641492,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-07-07T00:01:08.000Z","date":"2021-07-01","kind":"sale","acquired":false,"shares":805,"price":52.0062,"value":41864.991,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.83 to $52.39. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":257274,"source":{"system":"sec-edgar","filing":"0001725160-21-000163","document":"wf-form4_162561605028744.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000163/wf-form4_162561605028744.xml","form_type":"4"}},{"id":2641491,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-07-07T00:01:08.000Z","date":"2021-07-01","kind":"sale","acquired":false,"shares":1378,"price":51.1461,"value":70479.3258,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.71 to $51.57. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":258079,"source":{"system":"sec-edgar","filing":"0001725160-21-000163","document":"wf-form4_162561605028744.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000163/wf-form4_162561605028744.xml","form_type":"4"}},{"id":2641490,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-07-07T00:01:08.000Z","date":"2021-07-01","kind":"sale","acquired":false,"shares":700,"price":50.1043,"value":35073.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.68 to $50.58. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":259457,"source":{"system":"sec-edgar","filing":"0001725160-21-000163","document":"wf-form4_162561605028744.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000163/wf-form4_162561605028744.xml","form_type":"4"}},{"id":2670348,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T23:13:03.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":20250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 11, 2021 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date."}],"balance_after":20250,"derivative":{"exercise_price":24.46,"expiration_date":"2031-06-11","underlying":"Common Stock","underlying_shares":20250},"source":{"system":"sec-edgar","filing":"0001209191-21-040394","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000120919121040394/doc4.xml","form_type":"4"}},{"id":2686835,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-03T00:26:19.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":200,"price":54.9,"value":10980.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."}],"balance_after":260157,"source":{"system":"sec-edgar","filing":"0001725160-21-000135","document":"wf-form4_162267996393933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000135/wf-form4_162267996393933.xml","form_type":"4"}},{"id":2686834,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-03T00:26:19.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":2883,"price":53.9927,"value":155660.9541,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.47 to $54.43. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":260357,"source":{"system":"sec-edgar","filing":"0001725160-21-000135","document":"wf-form4_162267996393933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000135/wf-form4_162267996393933.xml","form_type":"4"}},{"id":2727558,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-05T20:27:34.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":1122,"price":60.1425,"value":67479.885,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.05 to $60.37. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":263240,"source":{"system":"sec-edgar","filing":"0001725160-21-000120","document":"wf-form4_162024643302022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000120/wf-form4_162024643302022.xml","form_type":"4"}},{"id":2727557,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-05T20:27:34.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":950,"price":59.8307,"value":56839.165,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $59.05 to $60.04. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":264362,"source":{"system":"sec-edgar","filing":"0001725160-21-000120","document":"wf-form4_162024643302022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000120/wf-form4_162024643302022.xml","form_type":"4"}},{"id":2727556,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-05T20:27:34.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":661,"price":58.0449,"value":38367.6789,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $57.64 to $58.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":265312,"source":{"system":"sec-edgar","filing":"0001725160-21-000120","document":"wf-form4_162024643302022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000120/wf-form4_162024643302022.xml","form_type":"4"}},{"id":2727555,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-05T20:27:34.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":350,"price":56.9943,"value":19948.005,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $56.56 to $57.47. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":265973,"source":{"system":"sec-edgar","filing":"0001725160-21-000120","document":"wf-form4_162024643302022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000120/wf-form4_162024643302022.xml","form_type":"4"}},{"id":2755901,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-06T21:46:35.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":83,"price":45.0606,"value":3740.0298,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $44.87 to $45.11. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":266323,"source":{"system":"sec-edgar","filing":"0001725160-21-000090","document":"wf-form4_161774546778863.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000090/wf-form4_161774546778863.xml","form_type":"4"}},{"id":2755900,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-06T21:46:35.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":149,"price":44.2148,"value":6588.0052,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $43.87 to $44.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":266406,"source":{"system":"sec-edgar","filing":"0001725160-21-000090","document":"wf-form4_161774546778863.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000090/wf-form4_161774546778863.xml","form_type":"4"}},{"id":2755899,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-06T21:46:35.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":13792,"price":43.3657,"value":598099.7344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $42.87 to $43.78. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":266555,"source":{"system":"sec-edgar","filing":"0001725160-21-000090","document":"wf-form4_161774546778863.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000090/wf-form4_161774546778863.xml","form_type":"4"}},{"id":2755898,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-06T21:46:35.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":3083,"price":43.4303,"value":133895.6149,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."}],"balance_after":280347,"source":{"system":"sec-edgar","filing":"0001725160-21-000090","document":"wf-form4_161774546778863.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000090/wf-form4_161774546778863.xml","form_type":"4"}},{"id":2814389,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-03T21:35:17.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":3083,"price":41.6745,"value":128482.4835,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."}],"balance_after":283430,"source":{"system":"sec-edgar","filing":"0001725160-21-000050","document":"wf-form4_161480729232378.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000050/wf-form4_161480729232378.xml","form_type":"4"}},{"id":2859496,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-17T00:05:20.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date."}],"balance_after":45000,"derivative":{"exercise_price":38.76,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001725160-21-000041","document":"wf-form4_161352028336636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000041/wf-form4_161352028336636.xml","form_type":"4"}},{"id":2859495,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-17T00:05:20.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date."}],"balance_after":286513,"source":{"system":"sec-edgar","filing":"0001725160-21-000041","document":"wf-form4_161352028336636.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000041/wf-form4_161352028336636.xml","form_type":"4"}},{"id":2882274,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-03T22:56:08.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":383,"price":38.3345,"value":14682.1135,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $38.09 to $38.55. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":271513,"source":{"system":"sec-edgar","filing":"0001725160-21-000022","document":"wf-form4_161239294791584.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000022/wf-form4_161239294791584.xml","form_type":"4"}},{"id":2882273,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-03T22:56:08.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":2700,"price":37.4528,"value":101122.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $36.90 to $37.79. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":271896,"source":{"system":"sec-edgar","filing":"0001725160-21-000022","document":"wf-form4_161239294791584.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000022/wf-form4_161239294791584.xml","form_type":"4"}},{"id":2916198,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-07T01:24:44.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":100,"price":53.2,"value":5320.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."}],"balance_after":274596,"source":{"system":"sec-edgar","filing":"0001725160-21-000005","document":"wf-form4_160998266964597.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000005/wf-form4_160998266964597.xml","form_type":"4"}},{"id":2916197,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-07T01:24:44.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":1583,"price":52.7337,"value":83477.4471,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.16 to $53.10. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":274696,"source":{"system":"sec-edgar","filing":"0001725160-21-000005","document":"wf-form4_160998266964597.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000005/wf-form4_160998266964597.xml","form_type":"4"}},{"id":2916196,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-07T01:24:44.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":600,"price":51.5822,"value":30949.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.07 to $51.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":276279,"source":{"system":"sec-edgar","filing":"0001725160-21-000005","document":"wf-form4_160998266964597.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000005/wf-form4_160998266964597.xml","form_type":"4"}},{"id":2916195,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-07T01:24:44.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":800,"price":50.3588,"value":40287.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.82 to $50.80. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":276879,"source":{"system":"sec-edgar","filing":"0001725160-21-000005","document":"wf-form4_160998266964597.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516021000005/wf-form4_160998266964597.xml","form_type":"4"}},{"id":2953688,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-09T01:38:13.000Z","date":"2020-12-07","kind":"sale","acquired":false,"shares":391,"price":54.3863,"value":21265.0433,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $54.15 to $54.89. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":277679,"source":{"system":"sec-edgar","filing":"0001725160-20-000059","document":"wf-form4_160747787744229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516020000059/wf-form4_160747787744229.xml","form_type":"4"}},{"id":2953687,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-09T01:38:13.000Z","date":"2020-12-07","kind":"sale","acquired":false,"shares":4983,"price":53.7111,"value":267642.4113,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.15 to $54.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":278070,"source":{"system":"sec-edgar","filing":"0001725160-20-000059","document":"wf-form4_160747787744229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516020000059/wf-form4_160747787744229.xml","form_type":"4"}},{"id":2953686,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-09T01:38:13.000Z","date":"2020-12-07","kind":"sale","acquired":false,"shares":971,"price":52.5293,"value":51005.9503,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.15 to $53.13. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":283053,"source":{"system":"sec-edgar","filing":"0001725160-20-000059","document":"wf-form4_160747787744229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516020000059/wf-form4_160747787744229.xml","form_type":"4"}}],"next_cursor":"2020-12-09T01:38:13.000000Z,2953686"}